Dermatologic diseases are the 4th most common cause of all human illnesses.
Every individual experiences a skin disease at least once during their lifetime.
7 of the 15 best selling drugs are already being used in dermatology today and many more promising treatments are in the pipeline.
based on clinical view and histopathology are imprecise and impede the optimal use of the already available highly specific modern therapies in dermatology.
is to offer modern diagnostics for modern therapies. With our first test – PsorEx – to differentiate between eczema and psoriasis on molecular level we achieved a milestone for molecular diagnostics in dermatology.
a comprehensive technological platform for fast and objective molecular diagnostics in dermatology to reduce health care costs and improve patient treatment.
Dermagnostix provides molecular diagnostic solution for dermatology.
Dermagnostix is a spin-off from the Hahn-Schickard Institut in Freiburg, the Helmholtz Zentrum München (HMGU) and TU München. We are located in Southern Germany (Baden-Wuerttemberg and Bavaria).
Our multidisciplinary team unites expertise in dermatology, basic research, microfluidics and artificial intelligence to bring the most innovative products to market.
Natalie Garzorz-Stark, MD, PhD, MHBA
Katharina Dormanns, PhD
CTO, Microfluidics Engineer
Prof. Kilian Eyerich, MD, PhD
Prof. Stefanie Eyerich, PhD
Prof. Kristian Reich, MD, PhD
Prof. Christoffer Gebhardt, MD, PhD
Prof. Fabian Theis, PhD, PhD
Lucca Weber, M.Sc.
Life Science Engineer
PD Nils Paust, PhD